28 research outputs found

    Dyslipidemia impairs mitochondrial trafficking and function in sensory neurons

    Full text link
    Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/154247/1/fsb2fj201700206r.pd

    Spontaneous Diabetes in Hemizygous Human Amylin Transgenic Mice That Developed Neither Islet Amyloid nor Peripheral Insulin Resistance

    Get PDF
    OBJECTIVES—We sought to 1) Determine whether soluble-misfolded amylin or insoluble-fibrillar amylin may cause or result from diabetes in human amylin transgenic mice and 2) determine the role, if any, that insulin resistance might play in these processes

    Effects of Aflatoxin B1 and Fumonisin B1 on the Viability and Induction of Apoptosis in Rat Primary Hepatocytes

    Get PDF
    The present study evaluated the effect of aflatoxin B1 (AFB1) and fumonisin B1 (FB1) either alone, or in association, on rat primary hepatocyte cultures. Cell viability was assessed by flow cytometry after propidium iodine intercalation. DNA fragmentation and apoptosis were assessed by agarose gel electrophoresis and acridine orange and ethidium bromide staining. At the concentrations of AFB1 and FB1 used, the toxins did not decrease cell viability, but did induce apoptosis in a concentration and time-dependent manner

    Putovanje kroz interakcije proteinskih kinaza aktiviranih mitogenima i okratoksina A

    Get PDF
    Ochratoxin A (OTA) is a ubiquitous mycotoxin with potential nephrotoxic, carcinogenic, and cytotoxic action. It has been proposed that OTA might be involved in the development of Balkan endemic nephropathy, which is associated with an increased risk of urinary tract tumours, and of other forms of interstitial nephritis. Cell susceptibility to OTA mainly depends on mycotoxin concentrations, duration of exposure, and intracellular molecular and genetic context. OTA can affect a cell by stimulating or inhibiting certain signalling pathways such as mitogen-activated protein kinase (MAPK). Three major mammalian MAPKs have been described: extracellular signal-regulated protein kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 MAPK. All MAPKs regulate diverse cellular programmes, but in most cases ERKs have been linked to cell survival, while JNKs, and p38 MAPKs have been implicated in cell death by apoptosis. This review looks into OTA-mediated MAPK activation and its effects.Okratoksin A (OTA) posvuda je prisutan mikotoksin za koji se smatra da je potencijalno nefrotoksičan i karcinogen, a moĆŸe uzrokovati i smrt stanice. OTA se smatra mogućim uzročnikom balkanske endemske nefropatije koju karakterizira povećani rizik od razvoja tumora mokraćnog sustava te različitih drugih vrsta intersticijskog nefritisa. Osjetljivost stanice naspram OTA ovisi ponajprije o koncentraciji mikotoksina, vremenu izloĆŸenosti i o unutarstaničnome molekularnom i genskom sklopu. OTA moĆŸe djelovati na stanicu tako ĆĄto potiče ili inhibira određene signalne putove u stanici poput puta proteinskih kinaza aktiviranih mitogenima (MAPK). Tri glavne MAPK u sisavaca su proteinska kinaza regulirana izvanstaničnim signalima (ERK), kinaza koja fosforilira N-kraj transkripcijskog faktora c-Jun (JNK) i p38 MAPK. Svi članovi porodice MAPK reguliraju različite stanične programe, s time da ERK najčeơće stimuliraju preĆŸivljavanje stanica, dok JNK i p38 MAPK najčeơće uzrokuju umiranje stanica apoptozom. U ovome smo preglednom članku prikazali na koji način stanice odgovaraju na aktivaciju MAPK koju potiče OTA

    Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes

    Full text link
    ObjectiveThe global rise in type 2 diabetes is associated with a concomitant increase in diabetic complications. Diabetic polyneuropathy is the most frequent type 2 diabetes complication and is associated with poor outcomes. The metabolic syndrome has emerged as a major risk factor for diabetic polyneuropathy; however, the metabolites associated with the metabolic syndrome that correlate with diabetic polyneuropathy are unknown.MethodsWe conducted a global metabolomics analysis on plasma samples from a subcohort of participants from the Danish arm of Anglo‐Danish‐Dutch study of Intensive Treatment of Diabetes in Primary Care (ADDITION‐Denmark) with and without diabetic polyneuropathy versus lean control participants.ResultsCompared to lean controls, type 2 diabetes participants had significantly higher HbA1c (p = 0.0028), BMI (p = 0.0004), and waist circumference (p = 0.0001), but lower total cholesterol (p = 0.0001). Out of 991 total metabolites, we identified 15 plasma metabolites that differed in type 2 diabetes participants by diabetic polyneuropathy status, including metabolites belonging to energy, lipid, and xenobiotic pathways, among others. Additionally, these metabolites correlated with alterations in plasma lipid metabolites in type 2 diabetes participants based on neuropathy status. Further evaluating all plasma lipid metabolites identified a shift in abundance, chain length, and saturation of free fatty acids in type 2 diabetes participants. Importantly, the presence of diabetic polyneuropathy impacted the abundance of plasma complex lipids, including acylcarnitines and sphingolipids.InterpretationOur explorative study suggests that diabetic polyneuropathy in type 2 diabetes is associated with novel alterations in plasma metabolites related to lipid metabolism.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/167813/1/acn351367_am.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/167813/2/acn351367.pd

    Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes

    No full text
    ObjectiveThe global rise in type 2 diabetes is associated with a concomitant increase in diabetic complications. Diabetic polyneuropathy is the most frequent type 2 diabetes complication and is associated with poor outcomes. The metabolic syndrome has emerged as a major risk factor for diabetic polyneuropathy; however, the metabolites associated with the metabolic syndrome that correlate with diabetic polyneuropathy are unknown.MethodsWe conducted a global metabolomics analysis on plasma samples from a subcohort of participants from the Danish arm of Anglo‐Danish‐Dutch study of Intensive Treatment of Diabetes in Primary Care (ADDITION‐Denmark) with and without diabetic polyneuropathy versus lean control participants.ResultsCompared to lean controls, type 2 diabetes participants had significantly higher HbA1c (p = 0.0028), BMI (p = 0.0004), and waist circumference (p = 0.0001), but lower total cholesterol (p = 0.0001). Out of 991 total metabolites, we identified 15 plasma metabolites that differed in type 2 diabetes participants by diabetic polyneuropathy status, including metabolites belonging to energy, lipid, and xenobiotic pathways, among others. Additionally, these metabolites correlated with alterations in plasma lipid metabolites in type 2 diabetes participants based on neuropathy status. Further evaluating all plasma lipid metabolites identified a shift in abundance, chain length, and saturation of free fatty acids in type 2 diabetes participants. Importantly, the presence of diabetic polyneuropathy impacted the abundance of plasma complex lipids, including acylcarnitines and sphingolipids.InterpretationOur explorative study suggests that diabetic polyneuropathy in type 2 diabetes is associated with novel alterations in plasma metabolites related to lipid metabolism.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/167813/1/acn351367_am.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/167813/2/acn351367.pd
    corecore